GlassScriptPhysician profile
Kyi W Yu
NPI 1427095686
$8,361.70
in general payments reported to CMS, 2019-2025
52 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $1,027 · 2021: $1,468 · 2022: $951 · 2023: $1,532 · 2024: $1,345 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,321.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $803.16 | 2019-2025 | Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $701.91 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $689.70 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $485.20 | 2019-2025 | Mounjaro, Zepbound, Amyvid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $483.52 | 2019-2025 | Jardiance |
| Cumberland Pharmaceuticals, INC. | $479.80 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $464.06 | 2022-2025 | Vpriv |
| Biohaven Pharmaceuticals, INC. | $355.04 | 2020-2021 | |
| Glaxosmithkline, LLC. | $307.08 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $283.61 | 2019-2020 | |
| Genzyme Corporation | $269.54 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $233.12 | 2022 | |
| Merck Sharp & Dohme LLC | $228.06 | 2021-2024 | Verquvo, Lagevrio, Steglatro |
| Exact Sciences Corporation | $217.49 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $180.49 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyi Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.